Effect of Combination Therapy with Matrix Metalloproteinase Inhibitor MMI-166 and Mitomycin C on the Growth and Liver Metastasis of Human Colon Cancer

Manabu Ohta, Hiroyuki Konno, Tatsuo Tanaka, Megumi Baba, Kinji Kamiya, Kouji Oba, Takeshi Kaneko, Tsuyoshi Syouji, Akira Igarashi and Satoshi Nakamura
Department of Surgery II, Hamamatsu University School of Medicine, 3600 Handa-cho, Hamamatsu 431-3192

Several synthetic inhibitors of matrix metalloproteinases (MMPs) show antitumor, antimetastasis and antiangiogenesis effects in various models. Synergistic effects of combinations with conventional cytotoxic agents were reported previously. In this study, we examined the effects of a new selective MMP inhibitor, MMI-166, on tumor growth, angiogenesis and metastasis in a liver metastatic model of human xenotransplanted colon cancer (TK-4). We also investigated the synergistic effects of MMI-166 and a conventional cytotoxic agent, mitomycin C (MMC), in this model. Mice transplanted orthotopically with TK-4 were divided into 4 groups; a control group (treated with vehicle solution), an MMI-166 group in which MMI-166 was orally administered (p.o.) at a dose of 200 mg/kg, 6 days/week for 5 weeks, an MMC group in which MMC was administered intraperitoneally (i.p.) at a dose of 2 mg/kg/week for 5 weeks, and a combination group (treated with MMI-166 and MMC). MMI-166 did not inhibit transplanted tumor growth, but significantly inhibited liver metastasis compared with the control group and MMC group (P<0.01). Significant antitumor and antimetastatic effects of the combination therapy were demonstrated. The microvessel density (MVD) detected by immunohistochemical staining with ER-MP12 antibody tended to be lower in the MMI-166 and the combination groups. These results suggest that MMI-166 has potential anti-metastatic ability and a synergistic effect with MMC.

Key words: Matrix metalloproteinase inhibitor—Metastasis—Colon cancer—Mitomycin C

In tumor progression and metastasis, invasion and angiogenesis are essential. Among the various factors, matrix metalloproteinases (MMPs) play an important role in tumor invasion, as well as plasminogen activators, which function to degrade the extracellular matrix. Among the 18 MMPs identified to date, MMP-2 and MMP-9 have been reported to be associated with tumor invasion, metastasis and angiogenesis, and these factors have also been identified to have a prognostic impact in various malignancies. MMP-2 and MMP-9 have specific proteolytic activity against type IV collagen of the basement membrane. The expression of MMP-2, -9 correlates closely with invasive and metastatic potentials of several tumors \textit{in vivo}. A correlation between angiogenesis and MMPs was also reported.

Several MMP inhibitors including Batimastat, Marimastat, AG3340, BPHA, KB-R7785, R94138, CT1746 and BAY12-9566 have been synthesized as candidate drugs for cancer treatment. Most of them function to diminish the activity of MMP-2, -9, or -7. Antitumor effects of Batimastat on ovarian tumor, melanoma, colon cancer, breast cancer, hemangiomata, and lung cancer have been recognized. The MMP inhibitors Batimastat and Marimastat are presently undergoing Phase I, II and III clinical trials. BAY 12-9566 is in Phase I trial. Here, we examined a potent oral MMP inhibitor, MMI-166, which selectively inhibits MMP-2 and -9. Several MMP inhibitors reduce metastasis in various models by inhibiting angiogenesis. In this study, we examined the anti-tumor and anti-metastatic effects of MMI-166, and examined the microvessel density (MVD) to clarify the antiangiogenesis activity. Synergistic effects of MMP in combination with conventional cytotoxic agents were reported previously, and in this study we also examined the effect of MMI-166 and a conventional cytotoxic agent, mitomycin C (MMC), in a human colon cancer nude mouse model.

MATERIALS AND METHODS

Animals Male BALB/c \textit{nu/nu} mice were obtained from Clea, Japan, Inc. (Tokyo). Animals were used for this study at 5 weeks of age.

Materials Matrix metalloproteinase inhibitor MMI-166 was kindly provided by Shionogi Co., Ltd. (Osaka). Its \textit{in vitro} IC\textsubscript{50} values are 2 nM for gelatinase A (MMP-2) and 53 nM for gelatinase B (MMP-9). An aqueous suspension

E-mail: otam@hama-med.ac.jp
of MMI-166 (a white powder) was prepared by homogenizing the drug in 0.5% carboxymethyl cellulose Na, 0.9% benzyl alcohol and 0.4% Tween 80 in saline. A control solution of the vehicle without MMI-166 was also prepared. MCC was purchased from Kyowa Hakko (Tokyo) and dissolved in saline.

**Preparation of human colon cancer xenografts** Human colon cancer xenograft, TK-4 (a well-differentiated carcinoma line) was used in this study (Fig. 1). This xenograft was established from surgical specimens in our department and was maintained by serial transplantation in nude mice. In gelatin zymography, TK-4 tumors expressed MMP-2, but the expression of MMP-9 was not recognized (data not shown).

**Experimental design** For the xenograft orthotopic transplantation, tumor tissue specimens weighing 200 mg were sutured onto the surface of the cecum. Mice were randomly divided into 4 groups and the experiment was started on day 5 after transplantation. The groups were the control group treated with the same volume of vehicle, the MMC group in which animals were given MMC i.p. at a dose of 2 mg/kg/week for 5 weeks, the MMI-166 group in which animals were given MMI-166 p.o. at a dose of 200 mg/kg, 6 days/week for 5 weeks, and the combination group in which animals were given MMC i.p. at a dose of 2 mg/kg/week and MMI-166 p.o. at a dose of 200 mg/kg, 6 days/week for 5 weeks. Mice were sacrificed on day 40 after transplantation. The mice were weighed and autopsy was performed immediately. The tumors growing on the cecal wall were removed and weighed. One part of the tumor was placed in 10% formalin, embedded in paraffin, sectioned, and stained with H&E. The other part was placed in Tissue-Tek O.C.T. Compound (Sakura Finetech- nical Co., Ltd., Tokyo), and then snap-frozen and stored at −80°C for immunohistochemistry and gelatin zymography. The liver metastases were counted macroscopically and subjected to routine histological examinations (Fig. 2).

**Immunohistochemical analysis for MVD** Intratumoral microvessels were determined by immunostaining using a rat monoclonal antibody (ER-MP12) with the avidin-biotin-peroxidase complex technique as previously described. For determination of the MVD in transplanted tumors, the three most vascular areas within one section were chosen and the stained vessels were counted under a light microscope at 200-fold magnification. The average count was recorded as the MVD for each animal.

**Statistical analysis** The statistical analysis was performed with Student’s *t* test and the χ² test, and *P* < 0.05 was taken as the criterion of statistical significance.

**RESULTS**

**Therapeutic effect on tumor growth and liver metastasis** All tumor pieces transplanted in the cecum grew, as previously reported. Actual tumor weights in each group were as follows: control group, 1.102±0.96 g; MMC

![Fig. 1. TK-4 (a well-differentiated adenocarcinoma), which was established in Department of Surgery II, Hamamatsu University School of Medicine. Bar 50 µm. Liver metastatic rate of orthotopic implantation is 60–84%.](image-url)
group, 0.807±0.96 g; MMI group, 1.175±0.130 g; and combination group, 0.501±0.052 g. Administration of MMC significantly inhibited the primary tumor growth \((P<0.03)\), but no such antitumor effect of MMI-166 administration was observed. Combination therapy amplified the inhibitory effect on tumor growth compared with MMC therapy \((P<0.013)\) (Fig. 3).

Histological difference between the tumors treated with and without MMI-166 was clearly apparent (Fig. 4). The tumor margin adjacent to normal tissue in the cecal wall could be readily identified in the MMI and the combination groups, whereas cancer nests invaded the cecal submucosa in the control group.

Table I shows the numbers of mice with liver metastasis and metastatic foci in the four groups. No liver metastasis developed in the MMI-166 and combination groups \((P<0.01)\), although it was observed in mice of the control groups and in mice of the MMC group. MMC failed to inhibit liver metastasis.

**Immunohistochemical analysis for MVD** In all three treated groups, MVD was significantly reduced compared with the control group. Development of microvessels was inhibited in the three treated groups. MVD in the combination therapy was lowest among the groups, although the difference was not significant \((P=0.155\) vs. MMI, \(P=0.13\) vs. MMI-166\) (Fig. 5).

**Body weight and spleen weight** No significant differences in body weight and spleen weight were found in the 4 groups, and there were no severe side effects in any group (Fig. 6).

**DISCUSSION**

We demonstrated here that the orally active MMP inhibitor, MMI-166, has antimetastatic efficacy. This is the first report to describe the antimetastatic efficacy of an
Combination Therapy with MMP Inhibitor and MMC

orally active MMP inhibitor in a nude mouse liver-metastatic model. Furthermore, the synergy of antimetastasis and antiangiogenesis actions of this inhibitor and MMC was clearly apparent in our model. Previously, we investigated and reported the antimetastatic effects of various angiogenesis inhibitors, and the inhibitory effect of MMI-166 was as potent as that of TNP-470 or VEGF-neutralizing antibody.34, 35)

Several MMP inhibitors have been demonstrated to have antiangiogenic activity, mainly because the degradation of ECM is essential to the process of angiogenesis. It has been shown in several studies with different

---

Table I. Inhibitory Effect of MMI-166 and MMC on Liver Metastasis

| Group          | Number of mice with liver metastasis (%) | Mean number of metastatic liver foci |
|----------------|------------------------------------------|-------------------------------------|
| A (Control)    | 9/15 (60)\(ad\)                          | 1.40±0.35\(d\)                     |
| B (MMC)        | 7/15 (46.7)\(a\)                         | 1.68±0.49\(a\)                     |
| C (MMI-166)    | 0/14 (0)\(b\,e\)                        | 0.00\(c\,e\)                       |
| D (MMC+MMI-166)| 0/13 (0)\(b\,e\)                         | 0.00\(c\,e\)                       |

\(a\) NS, \(b\) \(P<0.01\), \(c\) \(P<0.001\), relative to control by Student’s \(t\) test.
\(d\) NS, \(e\) \(P<0.01\), relative to group B (MMC) by Student’s \(t\) test.

---

Fig. 4. Histological appearance from the invaded lesion from the implanted tumor. A: Massive invasion of cancer cells is observed in the control group. B: The layered construction of the cecum in the MMI-166 group is maintained. Bar 50 \(\mu\)m.

Fig. 5. The MVD visualized by immunohistological staining with ER-MP12 antibody. ∗ \(P<0.027\), ∗∗ \(P<0.0017\), ∗∗∗ \(P<0.001\), from control. Error bars, SD.
approaches that synthetic MMP inhibitors can inhibit angiogenesis in malignant tumors. Schnapper et al. demonstrated the importance of type IV collagenases in new blood vessel formation in an in vitro model of angiogenesis. Furthermore, vascular endothelial growth factor (VEGF) expression was significantly related to expression of MMP-2 in breast cancer and lung cancer. Thymidine phosphorylase expression was also correlated to pro MMP-2 and activated MMP-9 expression. In MMP-2-deficient mice, tumor-induced angiogenesis was suppressed according to dorsal air sac assay, and the implanted tumor volume decreased for B16-BL16 melanoma and Lewis lung carcinoma. MMP-2 is expressed in several tumors and is related to prognosis and angiogenesis.

Considering that MMI-166 selectively inhibited both MMP-2 and MMP-9, and only MMP-2 is expressed in TK-4, inhibition of MMP-2 activity of TK-4 is crucial in preventing liver metastasis of this strain (data not shown). MMP-2 has been reported to enhance tumor angiogenesis. Histological findings revealed that MMI-166 was effective in reducing not only tumor angiogenesis, but also tumor invasion. The tumor margin adjacent to normal tissue in the cecal wall could be identified clearly in the groups treated with MMI-166. This suggested that the tumor invasion was inhibited by MMI-166, and this might have contributed to the antimetastatic effect. In the metastatic sites, however, MMP inhibitors may not inhibit the extravasation of tumor cells. Wylie et al. showed by intravital videomicroscopy that Batimastat did not affect the extravasation of cells from the liver circulation, whereas it reduced the mean diameter of liver metastasis after injection of B16F1 melanoma cells in a mouse model.

Interestingly, Lozonschi et al. found differences of inhibitory pattern on tumor angiogenesis between the MMP inhibitor KB-R7785, and TNP-470, a fumagillin derivative. Administration of MMP inhibitor reduced the expansion of vascular areas, generating centrally avascular tumors with only a rim of peripheral neovascularization in a dorsal skin chamber model. Avascular areas, however, were not seen after administration of TNP-470, as opposed to KB-R7785. TNP-470 did not affect the vascular density, but affected the vessel diameter. These findings suggested that KB-R7785 may primarily affect the early steps of angiogenesis, while TNP-470 may interfere more with later steps, possibly including maturation of newly formed vessels. Therefore, there may be a synergistic inhibitory effect of combined therapy with MMP inhibitor and TNP-470 on tumor angiogenesis.

Because MMC also inhibited the MVD in the primary tumors (Fig. 5), MMC may have a cytotoxic effect on both tumor cells and endothelial cells. However, the number of metastatic foci in the liver was not decreased by MMC treatment. It is possible that MMC may have a cytotoxic effect on endothelial cells after the tumor reaches a certain volume.

An enhanced effect of MMI-166 and MMC was also demonstrated in the present study. Several reports have revealed synergistic effects of MMP inhibitors and cytotoxic agents in vivo. The combination of either Batimastat or Marimastat and either cisplatin or cyclophosphamide has synergistic antitumor and survival-prolongation effects in lung and ovarian cancer mouse models. The combination of MMC and R94138 showed an increased preventive effect on peritoneal dissemination in a nude mouse model. The mechanisms of antitumor action of these combinations are not yet known. In a study of induction of Fas-mediated apoptosis in Ewing’s sarcoma cell lines, a combination effect of MMP inhibitors and doxorubicin was observed. In another report, the combination of Batimastat and interferon γ showed a strong synergistic effect in an ovarian cancer model in vivo. In addition, our previous study revealed an enhanced therapeutic effect of VEGF neutralizing antibody and MMC. The combi-
nation of antiangiogenic therapy and chemotherapy thus appears to be a useful strategy for colorectal cancer. Though the mechanisms of these combination therapies remain unclear, the combination of MMP inhibitors with chemotherapeutic agents or other antiangiogenic agents may be an option for cancer treatment.

Pan-MMP inhibitors have been reported to have adverse effects. Marimastat, which inhibits MMP-1, 2, 3, 7, 9, 12, commonly induces musculoskeletal events such as inflammation of the tendons and ligaments. In patients treated with BAY12-9566, which inhibits MMP-2, 3, 9, such musculoskeletal events were not observed in a Phase I study and other early clinical studies. In the present study, MMI-166 did not induce body weight loss or other serious adverse effects, probably because of its narrow inhibitory spectrum.

In conclusion, our results indicate that MMI-166 has potential antimetastatic ability and a synergistic therapeutic effect with MMC. The advantages of MMI-166 in clinical use are as follows. 1) MMI-166 has a small molecular weight and can be orally administered, which may improve patient compliance. 2) The adverse effects are less than those of broad-type MMP inhibitors and cytotoxic agents. 3) The synergistic effect with cytotoxic agents may afford amplified antitumor and antimetastatic potential.

ACKNOWLEDGMENTS

We thank Ryuji Maekawa PhD. and Takayuki Yoshioka PhD. (Discovery Research Laboratories, Shionogi Co., Ltd.) for providing the MMP inhibitor and for helpful suggestions during this study.

(Received January 22, 2001/Revised March 30, 2001/Accepted April 6, 2001)

REFERENCES

1) Maekawa, R., Maki, H., Yoshida, H., Hojo, K., Tanaka, H., Wada, T., Uchida, N., Takeda, Y., Kasai, H., Okamoto, H., Tsuzuki, H., Kambayashi, Y., Watanabe, F., Kawada, K., Toda, K., Ohtani, M., Sugita, K. and Yoshioka, T. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonfonyl-phenylalanine hydroxamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res., 59, 1231–1235 (1999).

2) Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H. and Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 58, 1048–1051 (1998).

3) Bromhall, S. R. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to clinical application. Int. J. Pancreatol., 21, 1–12 (1997).

4) Pyke, C., Raflikar, E., Huhitalsa, P., Hurskainen, T., Dano, K. and Tryggvason, K. Localization of messenger RNA for Mr 72 000 and 92 000 type IV collagenase in human skin cancer by in situ hybridization. Cancer Res., 52, 1336–1341 (1992).

5) Liotta, L. A. Tumor invasion and metastasis—role of the extracellular matrix: Rhoads memorial award lecture. Cancer Res., 46, 1–7 (1986).

6) Kurizaki, T., Toi, M. and Tominaga, T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol. Rep., 5, 673–677 (1998).

7) Heppner, K. J., Matrisian, L. M., Jensen, R. A. and Rodgers, W. H. Expression of matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol., 149, 273–282 (1996).

8) Sier, C. F., Kuppen, F. J., Ganesh, S., Heerding, M. M., Griffioen, G., Hanemaaijer, R., Krieken, J. H. J. M., Lamers, C. B. H. W. and Versavel, H. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer, 74, 413–417 (1996).

9) Taraboletti, G., Garofalo, A., Beloti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P. D. and Giavazzi, R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst., 87, 293–298 (1995).

10) Collier, I. E., Wilhelm, S. M., Eisen, A. Z., Marmer, B. L., Grant, G. A., Seltzer, J. L., Kronberger, A., He, C., Bauer, E. A. and Goldberg, G. I. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a signal metalloproteinase capable of degrading basement membrane collagen. J. Biol. Chem., 263, 6579–6587 (1988).

11) Sterns, M. E. and Wang, M. Type IV collagenase (MR 72 000) expression in human prostate: benign and malignant tissue. Cancer Res., 53, 878–883 (1993).

12) Prontera, C., Mariani, B., Rossi, C., Poggi, A. and Rotilio, D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int. J. Cancer, 81, 761–766 (1999).

13) Wylie, S., MacDonald, I. C., Varghese, H. J., Schmidt, E. E., Morris, V. L., Groom, A. C. and Chambers, A. F. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin. Exp. Metastasis, 17, 111–117 (1999).

14) Giavazzi, R., Garofalo, A., Ferri, C., Lucchini, V., Bone, E. A., Chiari, S., Brown, P. D., Nicoletti, M. I. and Taraboletti, G. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res., 4, 985–992 (1998).

15) Brucke, F., East, N., Upton, C., Patel, K. and Balkwill, F. R.
Interferon gamma induces cell cycle arrest and apoptosis in model of ovarian cancer: enhancement of effect by batimastat. *Eur. J. Cancer*, 33, 1114–1121 (1997).

16. Eccles, S. A., Box, G. M., Court, W. J., Bone, E. A., Thomas, W. and Brown, P. D. Control lymphatic and hematogenous metastasis of a rat mammary carcinoma by matrix metalloproteinase inhibitor batimastat. *Cancer Res.*, 56, 2815–2822 (1996).

17. Sledge, G. W., Quali, M., Goulet, R., Bone, E. A. and Fife, R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regression and metastasis in athymic mice. *J. Natl. Cancer Inst.*, 87, 1546–1550 (1995).

18. Watson, S. A., Morris, T. M., Robinson, G., Crimmin, M. J., Brown, P. D. and Hardcastle, J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models. *Cancer Res.*, 55, 3629–3633 (1995).

19. Chirivi, R. G. S., Garofalo, A., Crimmin, M. J., Bawden, L. J., Stoppacciaro, A., Brown, P. D. and Giavazzi, R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. *Int. J. Cancer*, 58, 460–464 (1994).

20. Davies, B., Brown, P. D., East, N., Crimmin, M. J. and Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. *Cancer Res.*, 53, 2087–2091 (1993).

21. Watson, S. A., Morris, T. M., Collins, H. M., Bawden, L. J., Hawkins, K. and Bone, E. A. Inhibition of tumor growth by batimastat in human xenograft model of gastric cancer: relationship with level of circulation CEA. *Br. J. Cancer*, 81, 19–23 (1999).

22. Price, A., Shi, Q., Morris, D., Wilcox, M. E., Brasher, P. M., Newcastle, N. B., Shalinsky, D., Zou, H., Appelt, K., Johnston, R. N., Yong, V. W., Edwards, D. and Forsyth, P. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG17339. *Cancer Res.*, 58, 845–854 (1999).

23. Lozonschi, L., Sunamura, M., Kobari, M., Egawa, S., Ding, L. and Matsuno, S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. *Cancer Res.*, 59, 1252–1258 (1999).

24. Igarashi, N., Kubota, T., Otani, Y., Matsuzaki, S. W., Watanabe, M., Teramoto, T., Kumai, K., Tamaki, K., Tanzawa, K., Kobayashi, T. and Kitajima, M. Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice. *Jpn. J. Cancer Res.*, 90, 116–121 (1999).

25. Anderson, I. C., Shipp, M. A., Docherty, J. P. and Teicher, B. A. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduce local invasion and metastasis of murine Lewis lung carcinoma. *Cancer Res.*, 56, 715–718 (1996).

26. Rowinsky, E. K., Humphrey, R., Hammond, L. A., Aylesworth, C., Smetzer, L., Hidalgo, M., Morrow, M., Smith, L., Garner, A., Sorensen, J. M., Von Hoff, D. D. and Eckhardt, S. G. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. *J. Clin. Oncol.*, 18, 178–186 (2000).

27. Parsons, S. L., Watson, S. A. and Steele, R. J. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. *Eur. J. Surg. Oncol.*, 23, 526–531 (1997).

28. Wojtowicz-Praga, S., Low, J., Marshall, J., Ness, E., Dickson, R., Barter, J., Sale, M., McCann, P., Moore, J., Cole, A. and Hawkins, M. J. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. *Invest. New Drugs*, 14, 193–202 (1996).

29. Nemunaitis, J., Poole, C., Primrose, J., Rosemurgy, A., Malfetano, J., Brown, P., Berrington, A., Cornish, A., Lynch, K., Rasmussen, H., Kerr, D., Cox, D. and Millar, A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor Marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term study. *Cancer Res.*, 61, 1101–1109 (1998).

30. Miller, A. W., Brown, P. D., Moor, J., Galloway, W. A., Cornish, A. G. and Lenehan, T. J. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. *Br. J. Clin. Pharmacol.*, 45, 21–26 (1998).

31. Rasmussen, H. S. and McCann, P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on Batimastat and Marimastat. *Pharmacol. Ther.*, 75, 69–75 (1997).

32. Kamiya, K., Konno, H., Tanaka, T., Baba, M., Matsumoto, K., Sakaguchi, T., Yukita, A., Asano, M., Suzuki, H., Arai, T. and Nakamura, S. Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody. *Jpn. J. Cancer Res.*, 90, 794–800 (1999).

33. Tanaka, T., Konno, H., Matsuda, I., Nakamura, S. and Baba, S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. *Cancer Res.*, 55, 836–839 (1995).

34. Kanai, K., Konno, H., Tanaka, T., Baba, M., Matsumoto, K., Nakamura, S., Yukita, A., Asano, M., Suzuki, H. and Baba, S. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. *Int. J. Cancer*, 77, 933–936 (1998).

35. Konno, H., Tanaka, T., Matsuda, I., Maruo, Y., Nishino, N., Nakamura, S. and Baba, S. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and Mitomycin C on the growth and liver metastasis of human colon cancer. *Int. J. Cancer*, 61, 268–271 (1995).

36. Schnaper, H. W., Grant, D. S., Stetler-Stevenson, W. G.,
Fridman, R., D'Orazi, G., French, A. N., Quigley, J. P. and Kleinman, H. K.  Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro.  *J. Cell. Physiol.*, 156, 235–246 (1993).

37) Tolnay, E., Wiethege, T., Kuhnen, C., Wulf, M., Voss, B. and Muller, K. M.  Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer.  *J. Cancer Res. Clin. Oncol.*, 123, 652–855 (1997).

38) Mitsiades, N., Poulaki, V., Leone, A. and Tsokos, M.  Fas-mediated apoptosis in Ewing’s sarcoma cell lines by metalloproteinase inhibitors.  *J. Natl. Cancer Inst.*, 91, 1678–1684 (1999).

39) Matsumoto, K., Konno, H., Tanaka, T., Baba, M., Kanai, T., Kamiya, K., Ohba, K. and Nakamura, S.  Combination therapy of vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft.  *Jpn. J. Cancer Res.*, 91, 748–752 (2000).

40) Shah, A., Sunderson, P., Humphrey, R. and Heller, A. H.  Comparative pharmacokinetics of BAY 12-9566, a metalloproteinase inhibitor, in healthy volunteers and cancer patients.  *Proc. Am. Assoc. Cancer Res.*, 39, 521 (1998).

41) Flynn, C., Bull, C., Eberwein, D., Matherne, C. and Himner, B.  Anti-angiogenetic activity of BAY12-9566 in human colon carcinoma HCT116 orthotopic model.  *Proc. Am. Assoc. Cancer Res.*, 39, 301 (1998).